Seres Therapeutics (MCRB) Prices 10.5M Share Common Offering at $21.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Seres Therapeutics (MCRB) to Offer 8M Common Shares
August 11, 2020 5:48 PM EDTSeres Therapeutics, Inc. (Nasdaq: MCRB) is commencing an underwritten registered public offering of 8,000,000 shares of its common stock. As part of this offering, Seres intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common... More
Seres Therapeutics (MCRB) Files to Offer 8M Shares of Common Stock
August 11, 2020 5:33 PM EDTSeres Therapeutics (NASDAQ: MCRB) disclosed:
We are offering 8,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market, or Nasdaq, under the symbol MCRB. On August 10, 2020, the last reported sale price of our common stock was $22.70 per... More
Seres Therapeutics (MCRB) PT Raised to $24 at Goldman Sachs
August 11, 2020 6:41 AM EDTGoldman Sachs raised its price target on Seres Therapeutics (NASDAQ: MCRB) to $24.00 (from $6.00) while maintaining a Neutral rating.... More
UPDATE: Jefferies Upgrades Seres Therapeutics (MCRB) to Buy
August 11, 2020 4:27 AM EDT(Updated - August 11, 2020 4:48 AM EDT)
(updating comment)
Jefferies analyst Chris Howerton upgraded Seres Therapeutics (NASDAQ: MCRB) from Hold to Buy with a price target of $29.00 (from $4.00).
The analyst comments "Despite ~400% move on positive rCDI data yesterday, we still... More
